- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01553773
Postmenopausal Facial Skin After Estradiol and Genistein Topical Treatment
Hyaluronic Acid Concentration in Postmenopausal Facial Skin After Estradiol and Genistein Topical Treatment: Double-blind and Randomized Clinical Trial of Efficacy
Study Overview
Detailed Description
Postmenopausal volunteers were recruited in Brazil from the Endocrinological Gynecology Division of the Gynecology Department of Federal University of São Paulo (UNIFESP). All women participated in this prospective, randomized, double-blind and estrogen-controlled study and approved by the local Ethics and Research Committee (Report No 386/2004). The evaluation of all of the subjects consisted of a detailed history, a physical exam, and a laboratory workup. The study protocol was approved by the UNIFESP School of Medicine Human Investigation Committee, and every participant had to provide written informed consent before enrollment.
Intervention Independent pharmacists dispensed either isoflavone or estrogen containers according to a computer-generated randomization list. The containers, as well as a jar for treatments, had identical appearance and color. The researchers were responsible for seeing the women allocated the next available number on entry into the trial, and each woman collected her containers directly from the pharmacy department. The code was revealed to the researchers once recruitment, data collection, and histological analyses were complete. If a health problem occurred, an independent physician who was blinded to the patient's treatment group examined her. If necessary, this physician prescribed laboratory exams for exclusion of any serious systemic side-effects. A number two punch biopsy of facial skin from the preauricular area was performed before and after the 24-week gel treatment. The women applied the gel on their facial skin daily at night, and in the morning, they used a gel sunscreen only. They were advised not to use any other cream. To assess possible systemic hormonal effects, hormonal vaginal cytology samples were taken at all visits (baseline and after 6, 12, 18, and 24 weeks of treatment) and estradiol blood samples before and after the treatment.
Groups The participants flowed through each stage of the study. After the end of study, the label was opened, and the treatment groups with the same number were classified. Fifteen patients were required for each study group: group E, treated with a gel with 17-β estradiol 0.01% (n = 15), and group G, treated with a gel with isoflavones (genistein 4%) (n = 15).
Processing of the material After the collection, the biopsies were immediately fixed for 24 hours in 10% formaldehyde solution and then processed for paraffin via dehydration in ethanol in increasing concentrations, diaphanization in xylol and impregnation by liquid paraffin in drying oven set at a temperature of 60 °C (methodology recommended by Michalany, 1998). The paraffin blocks were submitted to cuts of 3 μm with a Minot microtome. The cuts for immunohistochemistry were placed on slides previously treated with silane to 5 % and brought to oven at 37 °C for 24 hours for drying. Additionally, sections were made of 20 μm and placed in tubes of 2ml for the biochemical processing.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Sao Paulo, Brazil, 04021003
- Department of Gynecology - UNIFESP
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- two to five years postmenopause;
- FSH > 40 mU/ml;
- estrogen levels < 20 pg/ml;
- body mass index (BMI) < 30 kg/m2
Exclusion Criteria:
- treatment with estrogens or soybeans for the previous 12 months;
- tobacco user;
- women who had a contraindication for hormone therapy, who had been using retinoids or herbal substances, and those who had a history of collagen diseases.
- also, strict vegetarianism, high fiber- or high soy-diet consumption;
- regular consumption of vitamin and mineral supplementation greater than the Recommended Dietary Allowances;
- antibiotic treatment;
- a history of chronic disorders, including endocrine or gynecological diseases or neoplasia, as well as benign breast disease; and
- regular use of medication known to interfere with the study endpoints.
- patients with cervico-vaginal cytology classified as Papanicolaou Class III or more were also excluded.
- participants with hypertension who were using two or more antihypertensive drugs were not included in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Isoflavone
a gel with isoflavones (genistein 4%)
|
treatments: a gel with 17-β estradiol 0.01% (n = 15) and a gel with isoflavones (genistein 4%).
The gels were applied once per day.
the lenght of treatment was 24 weeks.
Other Names:
|
Experimental: Estradiol
gel with 17-β estradiol 0.01%
|
a gel with 17-β estradiol 0.01%.
Once per day.
The lenght of treatment was 24 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analysis of hyaluronic acid concentration in postmenopausal facial skin
Time Frame: up to 6 months
|
A number two small punch biopsy of facial skin from the preauricular area was performed before and after the 24-week gel treatment.
|
up to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marisa T Patriarca, MD, PhD, Federal University of São Paulo
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UNIFESPMP#1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrophy
-
BionovoUnknownVaginal Atrophy | Vulvar AtrophyUnited States
-
Sun Pharmaceutical Industries LimitedTerminated
-
United States Army Research Institute of Environmental...RecruitingMuscular Disorders, Atrophic | Muscle Atrophy | Disuse Atrophy | Atrophy, Disuse | Disuse Atrophy Muscle of ThighUnited States
-
Robert WestermannWithdrawnMuscle Atrophy | ACL Tear | Quadriceps Muscle Atrophy | Muscle Atrophy, ProximalUnited States
-
University of JazanCompletedQuadriceps Muscle AtrophySaudi Arabia
-
DLR German Aerospace CenterCompletedMuscle; Atrophy, GeneralGermany
-
McMaster UniversityUnknownSarcopenia | Muscle Atrophy | Muscle Disuse AtrophyCanada
-
Petra LarmoTurun Gynekologikeskus Oy; Tekes - The Finnish Funding Agency for Technology...CompletedVaginal Atrophy | Vaginal Dryness | Vulvar Atrophy | Vulvar DrynessFinland
-
Sunnybrook Health Sciences CentreInnovation Fund of the Alternative Funding Plan from the Academic Health...Recruiting
Clinical Trials on isoflavone
-
Seoul National University HospitalCompletedAgeing | Photo-agingKorea, Republic of
-
University of East AngliaCompletedCardiovascular Disease Risk ReductionUnited Kingdom
-
National Nutrition and Food Technology InstituteCompleted
-
National Nutrition and Food Technology InstituteUnknownPeritoneal Dialysis PatientsIran, Islamic Republic of
-
National Cancer Institute (NCI)CompletedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Oral Cavity Verrucous Carcinoma | Tongue... and other conditionsUnited States
-
National Health Research Institutes, TaiwanGenovate Biotechnology Co., Ltd.,; Taiwan Biotech Co., Ltd.Unknown
-
Federal University of UberlandiaCompleted
-
Johns Hopkins UniversityNational Cancer Institute (NCI); Physicians LaboratoriesCompleted
-
Federal University of UberlandiaCompleted
-
Beth Israel Deaconess Medical CenterNichimo - Tokyo, JapanCompleted